This study aims to test a treatment for people with certain types of blood cancer: Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL). The treatment involves three drugs: Venetoclax, Obinutuzumab, and Epcoritamab. Venetoclax stops cancer cells from growing by blocking a protein they need. Obinutuzumab and Epcoritamab are special proteins called antibodies that help the immune system attack cancer cells. This study is for patients who have not yet received treatment for CLL or SLL.
- Participants will receive the treatment for up to 12 cycles, each lasting 28 days.
- Afterwards, regular follow-up visits will continue for up to 5 years to check patient health.
- Participants must be 18 or older and meet specific health requirements to join.
Throughout the study, patients will have blood tests and imaging scans like CT or MRI. They may also have bone marrow tests. This study aims to see if adding Epcoritamab can improve treatment results. Joining involves regular visits to the clinic, but it offers a chance to help find better treatments for these cancers. Always discuss with your doctor before joining any study.